Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids-Reference-Cited by-同舟云学术

Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids

Published:2015 Issue:11 Volume:38 Page:1752-1756
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Sakurada Takumi¹,Kakiuchi Soji²³,Tajima Soichiro⁴,Horinouchi Yuya¹,Konaka Ken¹,Okada Naoto¹,Nishisako Hirotaka¹,Nakamura Toshimi¹,Teraoka Kazuhiko¹,Kawazoe Kazuyoshi¹⁵,Yanagawa Hiroaki⁶,Nishioka Yasuhiko³,Ishizawa Keisuke¹⁵

Affiliation:

1. Department of Pharmacy, Tokushima University Hospital

2. Department of Medical Oncology, Institute of Biomedical Sciences, The University of Tokushima Graduate School

3. Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, The University of Tokushima Graduate School

4. Department of Pharmacy, Kyushu University Hospital

5. Department of Clinical Pharmacy, Institute of Biomedical Sciences, The University of Tokushima Graduate School

6. Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/38/11/38_b15-00435/_pdf

Reference30 articles.

1. 1) Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul., 38, 135–152 (1998).

2. 2) Taylor EC, Patel HH. Synthesis of pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl-L-glutamic acid (LY231514). Tetrahedron, 48, 8089–8100 (1992).

3. 3) Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 17, 1194 (1999).

4. 4) Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol., 21, 2636–2644 (2003).

5. 5) Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 6, 363–373 (2001).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial;Frontiers in Oncology;2023-11-06

2. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors;Oncology;2023-09-29

3. Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma;Frontiers in Immunology;2023-03-21

4. Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer;Frontiers in Surgery;2022-05-16

5. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study;The Oncologist;2022-03-24